Biologic Switch Timing and Risk of Infection in Patients With Ulcerative Colitis/Crohn’s Disease: A Retrospective Study
OSs were common and not associated with an increased risk of serious infection vs non-overlapping biologics. Shortened washout periods may pose minimal safety risks to patients while improving UC/CD therapy management and improving trial recruitment.
Authors
- Yong Lin (ORCID: https://orcid.org/0000-0002-5710-5036)
- Maria Wiekowski (ORCID: https://orcid.org/0009-0001-2922-3051)
- Annie J. Kruger (ORCID: https://orcid.org/0000-0001-8227-5996)
- Samantha Schilsky
- Meenakshi Bewtra (ORCID: https://orcid.org/0000-0002-6489-7043)
- Salvatore Badalamenti (ORCID: https://orcid.org/0000-0002-0394-0730)
- Andrew W. Roberts (ORCID: https://orcid.org/0000-0001-5347-7169)
- Nicolas Capit
- Flavio Dormont
- Jean–Frédéric Colombel
Institutions
- Sanofi (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Gastroenterology and Hepatology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1016/j.cgh.2025.01.028
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 3.63